The effect of tezepelumab on hospitalizations and emergency department visits in patients with severe asthma

Ann Allergy Asthma Immunol. 2020 Aug;125(2):211-214. doi: 10.1016/j.anai.2020.05.020. Epub 2020 May 28.

Authors

Jonathan Corren¹, Stephanie Chen², Luke Callan³, Esther Garcia Gil⁴

Affiliations

¹ Departments of Medicine and Pediatrics, David Geffen School of Medicine, University of California, Los Angeles Los Angeles, California. Electronic address: jcorren@ucla.edu.
² Biometrics, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.
³ BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
⁴ Global Medical Affairs, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain.

PMID: 32474159
DOI: 10.1016/j.anai.2020.05.020

No abstract available

Publication types

Letter
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Anti-Asthmatic Agents / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Asthma / drug therapy
Asthma / epidemiology*
Cytokines / immunology
Disease Progression
Double-Blind Method
Emergency Service, Hospital
Female
Hospitalization / statistics & numerical data*
Humans
Male
Middle Aged
Placebo Effect
Severity of Illness Index
Thymic Stromal Lymphopoietin
Young Adult

Substances

Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
Cytokines
tezepelumab
Thymic Stromal Lymphopoietin